Alpha-lipoic acid (thioctic acid) is an antioxidant; in the 3-week ALADIN trial in 328 people with type 2 diabetes and painful neuropathy, daily intravenous infusions of 600 or 1,200 mg reduced foot symptom scores more than placebo.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Alpha-lipoic acid (thioctic acid) is an antioxidant; in the 3-week ALADIN trial in 328 people with type 2 diabetes and painful neuropathy, daily intravenous infusions of 600 or 1,200 mg reduced foot symptom scores more than placebo. · pmid:8786016
A meta-analysis of four placebo-controlled trials (1,258 patients) found that three weeks of daily intravenous alpha-lipoic acid reduced neuropathic symptoms 24.1% more than placebo. · pmid:14984445
Proportion of the 2 claims about Alpha-lipoic acid standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Alpha-lipoic acid yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. · pmid 14984445 · 2004
Observational evidence· resolved human data at the emerging tier: thin, or contested
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). · pmid 8786016 · 1995
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.